Piper Sandler analyst Edward Tenthoff lowered the firm’s price target on Aptose Biosciences to $5 from $12 and keeps an Overweight rating on the shares. Aptose issued 2.1M shares at $1.90 to Hanmi and 5.6M shares at $1.71 raising gross proceeds of $13.7M to fund operations into Q4 2024, the firm notes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APTO:
- Aptose Biosciences Announces Regulation FD Disclosure Event
- Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
- Aptose Biosciences Issues Regulation FD Disclosure Statement
- Aptose Biosciences prices 4.9M shares at $1.71 in underwritten public offering
- Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
